Equine Alpha-2 Macroglobulin Safety Study and Clinical Observations
Alpha-2 Macroglobulin is a unique treatment of cartilage-based pathology and inflammatory arthritides. A proprietary kit has been developed and FDA approved in the human market. α2M can not only inhibit the associated inflammatory cascade but also disrupt the catabolic process of cartilage degeneration. α2M is a major plasma glycoprotein best known for its ability to inhibit a broad spectrum of serine, threonine and metalloproteases by a unique bait and trap method.
The goal of this study was to showcase the use of the Astaria Global proprietary kit (Alpha2EQ) system to concentrate equine α2M and utilize it in a variety of orthopedic issues, thus saving time, money and reducing risks associated with alternative treatments.
A pilot project utilizing four non-lame recipient mares was performed. Based on the pilot project results, the clinical study was performed as a multi-clinic study. Five equine hospitals participated in the study and each contributed patients for evaluation of safety as well as clinical response. No controls were utilized, and the results are reported only as reaction to injection and positive or negative clinical response.